Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Nanosphere; GE Healthcare; Rosetta; and More

NEW YORK (GenomeWeb) – Nanosphere announced this week that it intends to voluntarily delist its stock from the Nasdaq on or about June 30. The company is being acquired by Luminex for about $77 million.

GE Healthcare said this week that its life sciences business has opened its new 210,000 square-foot North American headquarters in Marlborough, Massachusetts. The HQ, which will be at full capacity in 2017, will employ more than 500 scientists and professionals in the Boston area, and will include 40,000 square feet of laboratories supporting cell and immune therapy research and development, early-stage drug development, biomanufacturing, as well as scientific and medical affairs support. The laboratories will also house GE's ninth global Fast Trak drug discovery facility, and GE's FlexFactory manufacturing platform.

Rosetta Genomics said this week that it has signed a new participation agreement with preferred provider organization Stratose as a preferred laboratory provider.

EpiBiome announced this week that it has secured $1 million in debt financing from Silicon Valley Bank. It plans to use the proceeds to ramp up automation, to advance its drug development efforts, and to purchase additional lab equipment for its new facility. This financing announcement follows the January close of EpiBiome's $6 million Series A funding round. EpiBiome was a graduate from the inaugural class of the Illumina Accelerator genomic company launch program.

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the GenomeWeb site.